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MacBeath and colleagues (Kaushansky et al., 2008) use a protein array technology to find binding partners of
ErbB4 in a genome-wide and quantitative fashion, shedding new light on how ErbB4 initiates cellular signal-
ing events and why ErbB4 is not a potent oncogene.Chemistry & Biology 15, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 753The ErbB protein family, also named the
epidermal growth factor receptors
(EGFR) family, is a subfamily of receptor
tyrosine kinases (RTKs) with four structur-
ally related members: EGFR, ErbB2,
ErbB3, and ErbB4. These receptors play
critical roles in a broad array of biological
processes, such as cell proliferation and
differentiation, and are essential for nor-
mal human development (Citri and
Yarden, 2006). For instance, insufficient
ErbB signaling is often associated with
neurodegenerative diseases, while over-
expression or constitutively active mu-
tants of ErbB receptors are commonly
observed in various cancers, suggesting
that their activity in vivo must be tightly
regulated. Therefore, it is of great interest
to understand the functions that ErbB
receptors play in cellular signaling net-
works. However, although the first three
members of this protein family are well
studied, little is known about ErbB4,
whose functions in vivo remain elusive.
In this issue of Chemistry & Biology,
MacBeath and colleagues utilize a quanti-
tative, non-biased, and high-throughput
method to elucidate the functions of
ErbB4 by determining the affinities and
identities of its downstream interaction
partners (Kaushansky et al., 2008).
ErbB4 and other members of the ErbB
family share the same structural topology,
with a ligand-binding extracellular region,
a single transmembrane domain, a cyto-
plasmic kinase catalytic domain, and
a C-terminal tail containing a number of
tyrosine residues. Interestingly, while
EGFR and ErbB4 are fully functional re-
ceptors for signaling, ErbB2 and ErbB3
are defective because ErbB2 has no solu-
ble ligands and the kinase domain of
ErbB3 is inactive. Therefore, ErbB4 isthought to initiate signaling by adopting
the same mechanism as EGFR, in which
ligand-induced homo- or heterodimeriza-
tion of the extracellular domains brings
two neighboring kinase domains to-
gether, resulting in an asymmetric con-
formational change and enabling cross-
phosphorylation of the C-terminal tails
(Zhang et al., 2006). This activation pro-
vides docking sites to recruit downstream
enzymes and adaptor proteins that
contain either SH2 (Src homology 2) or
PTB (phosphotyrosine-binding) domains,
which specifically recognize both phos-
photyrosine (pTyr) and its adjacent resi-
dues. Indeed, a recent structural study
of ErbB4 activation confirms this asym-
metric mechanism is well reserved among
ErbB family members (Qiu et al., 2008).
Furthermore, similar to EGFR, ErbB4 can
also form heterodimers with ErbB2 and
ErbB3. From all aspects, ErbB4 should
just be another potent oncogene as other
ErbB receptors are. This is not the case,
however, as ErbB4 can also act as a tumor
suppressor (Gallo et al., 2006). Why does
ErbB4 have such a remarkable capabil-
ity? The answer to this question may rely
on the identification of what signaling
pathways can be trigged by ErbB4. As
the first step, it will be useful to identify
SH2/PTB-containing proteins that inter-
act with ErbB4.
In order to study phosphorylation-de-
pendent protein-protein interactions, syn-
thetic pTyr-containing peptides are used
as surrogates of normally difficult to pre-
pare full-length phosphorylated proteins.
Phosphorylated peptides can act as sub-
stitutes for the full-length proteins since
SH2 and PTB domains normally bind and
recognize only a few amino acids that
flank a specific pTyr. However, becauseErbB4 contains multiple potential pTyr
sites and there are a large number of
SH2 (>100) and PTB (>40) domains in hu-
man genome, it is daunting and impracti-
cal to test each potential binding pair by
low-throughput biochemical analysis.
Fortunately, several high-throughput
approaches have already been devel-
oped. Bidlingmaier and Liu selected pro-
teins interacting with the autophosphory-
lation site (Y1173) of EGFR from a yeast
surface-displayed human cDNA library
by iteratively enriching clones that bind
to the corresponding pTyr peptide, which
should be applicable on the study of
ErbB4 as well (Bidlingmaier and Liu,
2006). Schulze et al. used a pair of phos-
phorylated and nonphosphorylated pep-
tides to pull down interacting proteins
from cell lysates that were isotope-la-
beled (Schulze et al., 2005). This permit-
ted a quantitative analysis with mass
spectrometry (MS) to distinguish phos-
phorylation-specific interaction partners
from nonspecific background. A few bind-
ing proteins for each ErbB receptor were
identified in this way. Neither method,
however, can provide a complete and
quantitative measurement of the ErbB
receptors with all SH2/PTB domains.
To overcome this challenge, MacBeath
and colleagues constructed a protein ar-
ray featuring almost every SH2 domain
and PTB domain in human genome
(Jones et al., 2006). They then performed
a thorough literature survey to find all
phosphorylation sites on ErbB receptors
and synthesized the corresponding fluo-
rescently labeled pTyr-containing pep-
tides. In the case of ErbB4, in which no
experimentally verified pTyr sites were
reported, four peptides with predicted
phosphorylation sites were prepared.
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PreviewFigure 1. Flowchart of Quantitative Mapping of ErbB Receptors Interactome
(1) Identification of pTyr sites by literature search or MS assay.
(2) Synthesis of fluorescently labeled pTyr-containing peptides.
(3) Detection of interaction with protein arrays.
(4) Bioinformatics analysis.These peptides were used to probe the
protein array in a series of concentra-
tion-dependent assays to determine the
binding affinity between each pTyr-con-
taining peptide and each protein on the
array (Figure 1). In addition to confirming
known interactions that had been re-
ported previously, more than 100 previ-
ously unrecognized interactions were
identified quantitatively by this high-
throughput platform, which are difficult
to acquire by other methods.
Continuing their efforts to understand
the paradoxical functions of ErbB4, Mac-
Beath and colleagues first identified 19
pTyr sites on ErbB4 by using tandem
MS, then applied their high-throughput
protein array analysis with these newly
identified pTyr-containing peptides
(Kaushansky et al., 2008). They identified
known interaction partners of ErbB4 as
well as a number of previously unknown
partners, one of which—signal transducer754 Chemistry & Biology 15, August 25, 200and activator of transcription 1 (STAT1)—
was confirmed to interact with ErbB4 by
further biochemical experiments.
This high-throughput approach to ex-
plore the entire interactome of ErbB4 re-
ceptor is a technical triumph, illustrating
that protein arrays offer an unparalleled
capability to simultaneously determine
the affinity between ErbB4 and every
SH2/PTB domain in human genome. In
addition, the quantitative nature of this
measurement makes it possible to draw
a picture of the interaction network at
any defined affinity threshold, providing
new insights into the signaling properties
of ErbB4 at different expression levels.
More importantly, this unbiased and
streamlined method is generally applica-
ble for the study of any receptor or non-
receptor tyrosine kinase, representing
a quantum leap toward the characteriza-
tion of all signaling networks regulated
by tyrosine phosphorylation. Finally,8 ª2008 Elsevier Ltd All rights reservedthese experiments provide a comprehen-
sive view of ErbB4 functions.
Surprisingly, ErbB4 is recognized by
fewer SH2 and PTB domains than
EGFR, ErbB2, and ErbB3, implying
ErbB4 activates fewer pathways than
other EGF family receptors. Therefore,
its unusual property to suppress tumor
growth may not result from its ability to
initiate some unknown signaling circuits,
but may instead result from its higher
selectivity in recruiting downstream part-
ners. Since ErbB4 can form heterodimers
with other ErbB receptors, ErbB4 may ex-
ert a negative dominant effect by forming
more benign heterodimers with itself,
thereby reducing the level of more onco-
genic ErbB dimers. It is tempting, there-
fore, to hypothesize that activation of
a greater number of signaling pathways
increases the likelihood of oncogenic
transformation, a hypothesis that will re-
quire much more testing, but whose
answers are within the reach of systems
biology.
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